EGF receptor family targets for cancer therapeutics /

Saved in:
Bibliographic Details
Other Authors: Burgess, Antony, 1946- (Speaker)
Format: Electronic Video
Language:English
Published: London : Henry Stewart Talks, 2007.
Series:Henry Stewart talks. Biomedical & life sciences collection. Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease.
Subjects:
Online Access:https://hstalks.com/bs/456/
Series
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000ngm a2200000 a 4500
001 HST1074_1_2
003 UkLoHST
006 m c
007 cr|cna|||a||||
007 vz|czazum
008 080121s2007 enk|||||||||||s|||v|eng d
028 5 0 |a 1074  |b Henry Stewart Talks 
035 |a (UkLoHST)456 
035 |a (UkLU-K)AC000390284 
040 |a UkLU-K  |b eng  |c UkLU-K 
100 1 |a Burgess, Antony,  |d 1946-  |4 spk  |9 109857 
245 1 0 |a EGF receptor family  |h [electronic resource] :  |b targets for cancer therapeutics /  |c Tony Burgess. 
260 |a London :  |b Henry Stewart Talks,  |c 2007. 
300 |a 1 online resource (1 streaming video file (45 min.) :  |b color, sound). 
490 1 |a Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease,  |x 2056-452X 
500 |a Animated audio-visual presentation with synchronized narration. 
500 |a Title from title frames. 
505 0 |a Contents: The association of the Epidermal Growth Factor Receptor (EGFR) with the tumorigenic state -- The four related members of the EGFR family (EGFR, erbB2, erbB3 and erbB4) -- Signaling of the activated receptors as either homo- or heteromeric oligomers -- Activation of the EGFR by excess ligand stimulation, receptor over-expression and/or mutation in many carcinomas -- Utility of antibodies and receptor kinase inhibitors which interfere with signaling from the EGFR family as agents in cancer therapy -- The three-dimensional structures for the extracellular domains of EGFR, erbB2, erbB3 and erbB4 and the discovery that EGFR, erbB3 and erbB4 undergo major conformational transitions when interacting with their ligands -- Development of antibodies (mab806) which reduce tumor formation from cells expressing either truncated D2-7 EGFR or over-expressed EGFR by binding to the receptor in a region normally masked by the dimerization of the EGFR extracellular domain -- Use of EGFR antagonists or inhibitors to increase tumor killing by cytotoxic anti-cancer drugs and/or radiation -- Improvement of tumor killing by combining EGFR antagonists and EGFR kinase inhibitors. 
506 |a Access restricted to subscribers. 
538 |a Mode of access: World Wide Web. 
650 2 |a Cells.  |9 109858 
650 2 |a Receptor Protein-Tyrosine Kinases.  |9 109859 
650 2 |a Receptor, Epidermal Growth Factor.  |9 109860 
650 2 |a Signal Transduction.  |9 109861 
650 2 |a Tumor Cells, Cultured.  |9 109862 
830 0 |a Henry Stewart talks.  |p Biomedical & life sciences collection.  |p Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease.  |9 109863 
856 4 0 |u https://hstalks.com/bs/456/ 
856 4 2 |u https://hstalks.com/bs/p/38/  |3 Series 
999 |c 215824  |d 215823